Clinical Trial Search

Primary: Number of Seroprotected Subjects Against Polyribosyl-Ribitol-Phosphate (PRP) — 132; 126; 114 Participants

Primary: Percent Change From Baseline in Parathyroid Hormone (PTH) During the Efficacy Period — -53.6; -55.6; -50.8 percent change

Primary: Proportion of Participants Without MR Scan-related Complications — 100 Percentage of participants

Primary: Change in IL-1α From Baseline. — 3.56; 3.88 pg/mL — p=.576

Primary: Medication Adherence — 77.96; 80.13; 64.87; 76.13 Percentage of doses taken — p=.005

Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) — -0.035; 0.066; 0.168; 0.198 Liters — p=<0.0001

Primary: Number of Subjects With Serious Adverse Events (SAEs) — 71; 42; 37 Participants

Primary: Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Antigens — 146; 156; 147; 147 Participants

Primary: Physiological Posterior Probability of Posttraumatic Stress Disorder (PTSD) as Determined From Psychophysiologic Responses During Script-Driven Mental Imagery at Month 1…

Primary: Change From Baseline to Week 12 in 1h Post-dose FEV1 — 0.28; 0.24; 0.17 Liters — p=0.006

Primary: Vibration Detection Threshold (VDT) — 26.3; 19 (um/sec)

Primary: The Maximum Observed Concentration of Midazolam After a Single Dose of Brodalumab — 11.5 nanograms per milliliter

Primary: Estimating Blood Loss at the End of Myomectomy - Hematocrit Percentage — -4.4; -4.0 hematocrit percentage

Primary: Physiological Posterior Probability of Posttraumatic Stress Disorder (PTSD) as Determined From Psychophysiologic Responses During Script-Driven Traumatic Memory…

Primary: Total Weight Change From Baseline at 12 Weeks in kg — -13.3; -5.5 kg